Igenica Garners $33,000,000 Series C Financing Round

  • Feed Type
  • Date
    6/12/2012
  • Company Name
    Igenica
  • Mailing Address
    863 Mitten Road Burlingame, CA 94010
  • Company Description
    Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer.
  • Website
    http://www.igenica.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the company’s monoclonal antibody pipeline toward clinical trials. These funds will also be used to apply Igenica’s unique discovery approach, consisting of the sTAg target discovery platform and the iTAb antibody discovery platform, toward the discovery of new monoclonal antibodies against a broad range of drug targets that have not been previously investigated for the treatment of cancer.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    The Column Group
  • Venture Investor
    5AM Ventures
  • Venture Investor
    OrbiMed Advisors

By posting a comment, you agree to our terms and conditions.